Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Human reproductive technologies include, Assisted Reproductive Technology (ART), prognostics, contraception, and same-sex procreation. ART aids in the treatment of low fertility or infertility using artificial insemination, artificial reproduction, cloning, cytoplasmic transfer, fertility medication, hormone treatment, and others.

The global human reproductive technologies market is estimated to account for US$ 28,426.7 Mn in 2019 in terms of value and US$ 34,228.3 Mn by the end of 2027.

Global Human Reproductive Technologies Market: Drivers

Increasing prevalence of maternal mortality is expected to propel growth of the global human reproductive technologies market over the forecast period. For instance, according to Maternal Mortality: 1990 to 2015 Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division, Sub-Saharan Africa recorded the highest ratio or maternal mortality, at 555 per 100, 000 live births, from 1990 to 2015. Moreover, the United Nations is focused on achieving the Sustainable Development Goals 2015 - 2030 global maternal mortality ratio target of less than 70 per 100 000 live births.

Moreover, decreasing birth rate is also expected to aid in growth of the market. For instance, according to National Vital Statistics System, the provisional number of births for the U.S. in 2018 was 3,788,235, registering a decrease of 2% from 2017 and the lowest number of births in 32 years.

North America held dominant position in the global human reproductive technologies market in 2019, accounting for 46.1% share in terms of value, followed by Europe and Asia Pacific, respectively.

Figure 1. Global Human Reproductive Technologies Market Share (%), by Value, by Region, 2019

Human Reproductive Technologies  | Coherent Market Insights

Global Human Reproductive Technologies Market: Restraints

Limited insurance coverage for ART is expected to hinder growth of the market. ART is a relatively new and yet to be fully proven process in many countries. Such a status causes insurance companies to be apprehensive about covering expenses. For instance, in Canada, there is limited fund for IVF and intracytoplasmic sperm injection and hence infertile couples have to bear the cost of treatment. The average cost for infertility treatment in Canada is quite expensive and ranges from between US$ 10,000 to US$ 20,000.

Moreover, infertility treatments may not prove to be conclusive or effective and thereby need to be repeated sometimes. Such a risk of repetition of procedures negatively affects the decision of the consumers and limits market growth.

request-sample

Human Reproductive Technologies Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 28,426.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 2.4% 2027 Value Projection: US$ 34,228.3 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Technology: Infertility Drugs, Contraceptive Drugs and Devices
Companies covered:

Abbott Laboratories, Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Cryos USA, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., Pantarhei Bioscience B.V., Cook Medical, Inc., Ferring Pharmaceuticals, Johnson & Johnson, Daré Bioscience, Inc., and Merck Serono.

Growth Drivers:
  • Increasing prevalence of maternal mortality
  • Increasing population, and increasing focus on family planning
Restraints & Challenges:
  • Limited insurance coverage for ART
  • Low adoption of emergency human reproductive technologies in emerging economies

Global Human Reproductive Technologies Market: Opportunities 

Increasing rate of literacy is expected to offer lucrative growth opportunities for players in the global human reproductive technologies market. For instance, according to United Nations Children's Fund, globally, the youth literacy rate increased from 83% to 91% during 1985-2018.

Moreover, R&D in male birth control pill is also expected to aid in growth of the market. For instance, in March 2018, researchers from the University of Washington presented positive results from a small clinical trial of 100 men for a male birth control pill that inhibits testosterone production.

The global human reproductive technologies market was valued at US$ 28,426.7 Mn in 2019 and is forecast to reach a value of US$ 34,228.3 Mn by 2027 at a CAGR of 2.4% between 2020 and 2027.

Figure 2. Global Human Reproductive Technologies Market Value (US$ Bn), and Y-o-Y Growth (%), 2019-2027

Human Reproductive Technologies  | Coherent Market Insights

Market Trends/Key Takeaways

Increasing population is expected to propel demand for emergency human reproductive technologies. For instance, according to projections by Population Reference Bureau (PRB) included in the 2018 World Population Data Sheet, the world population is expected to reach 9.9 billion by 2050, up 2.3 billion or 29% from an estimated 7.6 billion people in 2018.

However, low adoption of emergency human reproductive technologies in emerging economies is expected to act as a drag for the demand. For instance, according to PRB’s 2019 Family Planning Data Sheet, fewer than 15% of married women of reproductive age use a modern human reproductive technologies in Democratic Republic of the Congo. 

Global Human Reproductive Technologies Market: Competitive Landscape

Major players operating in the global human reproductive technologies include, Abbott Laboratories, Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Cryos USA, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., Pantarhei Bioscience B.V., Cook Medical, Inc., Ferring Pharmaceuticals, Johnson & Johnson, Daré Bioscience, Inc., and Merck Serono.

Global Human Reproductive Technologies Market: Key Developments

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2020, Evofem Biosciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel used to prevent pregnancy in females of reproductive potential for use as an on-demand method of contraception.

Major players in the market are also focused on adopting partnership strategies to expand their product portfolio. For instance, in May 2020, Daré Bioscience, Inc., a developer of women’s health solutions partnered with Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic development, under which Health Decisions will exclusively provide CRO services within the U.S. to support R&D of Daré’s pipeline of contraception, fertility, and gynecological disorders products.

Human reproductive technologies assist parents who are having troubles in pregnancies, and infertility issues. These technologies include Assisted Reproductive Technology (ART), prognostics, contraception, and same-sex procreation. ART aids in the treatment of low fertility or infertility using artificial insemination, artificial reproduction, cloning, cytoplasmic transfer, fertility medication, hormone treatment, and others.

Restraints of the Global Human Reproductive Technologies Market

Major factors hampering the growth of the human reproductive technologies market during the forecast period constitutes of limited insurance coverage for ART, and low adoption of emergency human reproductive technologies in emerging economies.

Key features of the study:

  • This report provides in-depth analysis of the global human reproductive technologies market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global human reproductive technologies market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Abbott Laboratories, Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Cryos USA, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., Pantarhei Bioscience B.V., Cook Medical, Inc., Ferring Pharmaceuticals, Johnson & Johnson, Daré Bioscience, Inc., and Merck Serono.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global human reproductive technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Human Reproductive Technologies Market, By Technology:
    • Infertility Drugs
    • Contraceptive Drugs and Devices
  • Global Human Reproductive Technologies Market, By Geography:
    • North America
      • By Technology
        • Infertility Drugs
        • Contraceptive Drugs and Devices
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Technology
        • Infertility Drugs
        • Contraceptive Drugs and Devices
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Technology
        • Infertility Drugs
        • Contraceptive Drugs and Devices
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Technology
        • Infertility Drugs
        • Contraceptive Drugs and Devices
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Technology
        • Infertility Drugs
        • Contraceptive Drugs and Devices
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Technology
        • Infertility Drugs
        • Contraceptive Drugs and Devices
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Abbott Laboratories*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Evofem Biosciences, Inc.
    • Actavis Generics (Teva Pharmaceutical Industries Ltd.)
    • Sun Pharmaceutical Industries Ltd.
    • Perrigo Company plc
    • Uniprix
    • Gavis Pharmaceuticals (Lupin Limited)
    • Sandoz International GmbH
    • Aurobindo Pharma Limited
    • HRA Pharma, SA
    • Other Major Players

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Technology
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario
  4. Global Human Reproductive Technologies Market, By Technology, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Infertility Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Contraceptive Drugs and Devices
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Human Reproductive Technologies Market, By Regions, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  6. Competitive Landscape
    • Company Profiles
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Evofem Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Actavis Generics (Teva Pharmaceutical Industries Ltd.)
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Perrigo Company plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Uniprix
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Gavis Pharmaceuticals (Lupin Limited)
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sandoz International GmbH
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Aurobindo Pharma Limited
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • HRA Pharma, SA
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Other Major Players
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 33 market data tables and 24 figures on “Human Reproductive Technologies Market – Global forecast to 2027.

Frequently Asked Questions

The global human reproductive technologies market was valued at US$ 28,426.7 Mn in 2019 and is forecast to reach a value of US$ 34,228.3 Mn by 2027 at a CAGR of 2.4% between 2020 and 2027.
Major factor driving the growth of global human reproductive technologies market during the forecast period include increasing prevalence of maternal mortality, and increasing population, and increasing focus on family planning.
Major factors hampering the growth of the human reproductive technologies market during the forecast period constitutes of limited insurance coverage for ART, and low adoption of emergency human reproductive technologies in emerging economies.
Contraceptive drugs and devices held dominant position in the global human reproductive technologies market in 2019.
North America human reproductive technologies market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Abbott Laboratories, Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Cryos USA, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., Pantarhei Bioscience B.V., Cook Medical, Inc., Ferring Pharmaceuticals, Johnson & Johnson, Daré Bioscience, Inc., and Merck Serono.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner